British Journal of Clinical Pharmacology

Article	Citations
Issue Highlights	80
	75
Issue Information	72
	66
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	66
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	57
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	56
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	55
Letter to the editor of the Brit J Clin Pharmacol on Hartjes et al. 2025 https://doi.org/10.1002/bcp.70176	55
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	48
Neck‐vein thrombosis during spaceflight	47
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	45
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	45
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	44
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	43
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	43
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	43
Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐	42
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	39
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	37
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	37
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	36
Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database	35
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	34
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	34

Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	34
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	33
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	31
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	31
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	31
Triple antithrombotic therapy and dual therapy – What is the evidence base?	31
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	31
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	30
Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	30
Modelling the progression of illicit substance use patterns from real‐world evidence	30
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	29
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	28
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	28
Potential drug–drug interactions when managing status epilepticus patients in intensive care: A cohort study	27
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	26
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	26
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	26
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	25
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	25
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	25
Lemborexant levels in breast milk after single doses in healthy, lactating women	25
Selected Abstracts from Pharmacology 2024	25
Antidepressants are not safe during pregnancy and in women of child‐bearing age	24
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	24
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	23
Medication compliance aids unpackaged: A national survey	23
Issue Information	23
The trajectory of pharmacometrics to support drug licensing and labelling	23
Predicting outcomes for spinal muscular atrophy: When the diagnosis no longer means what it used to mean	22
Coping with COVID: Preparing prescribers during the pandemic	22
Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study	22
Longitudinal monitoring of cabotegravir and rilpivirine exposure from hair strand concentrations	22
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach	22
Hospital pharmacists' opinions on a risk prediction tool for medication‐related harm in older people	22
Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients	22
Issue Highlights	22
A pharmacometrics model to define docetaxel target in early breast cancer	22
Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care	22
The impact of a preprescribing formative assessment on learning in final‐year medical students using hospital inpatient electronic prescribing systems	22
Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance	22
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing	22
	21
Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis	21
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant	21
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self‐controlled case series study	20
Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients	20
Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study	20
Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data	20
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations	20
Management of serotonin syndrome (toxicity)	20

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach	20
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice	19
Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023	19
The effects of saffron (Crocus sativus L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes m	19
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite	19
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria	19
Long‐term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?	19
Validation of self‐reported medication use applying untargeted mass spectrometry‐based metabolomics techniques in the Rhineland study	19
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper	19
From statistical inference to machine learning: A paradigm shift in contemporary cardiovascular pharmacotherapy	19
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report	18
Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach	18
Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages	18
Performance of the ChatGPT large language model for decision support in community pharmacy	18
Correction	18
	18
Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis	18
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants	18
Variability in the prevalence of inappropriate medication use among older adults: A review highlighting the importance of screening methods and database types	18
Spotlight commentary: Innovations in clinical trials	18
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis	18
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers	18
Student perspectives on AI‐supported formative assessment in pharmacology	18
Epigenetic modifications in drug‐induced liver injury: A systematic review	18
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	18
	18
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation	18
The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study	17
Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model	17
Do we become better prescribers after graduation: A 1‐year international follow‐up study among junior doctors	17
Cefuroxime axetil dosing regimens and probability of target attainment in adults and children	17
Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties	17
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients	17
Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis‐inspired systematic review	17
Physostigmine should be used more readily for antimuscarinic toxicity: CON	16
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment	16
Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning	16
Assessment and evaluation of prescribing competences: A systematic review and recommendations	16
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy	16
Issue Highlights	16
Assessing the feasibility of infusing slow normal saline through a three‐metre‐longline to maintain patency of a peripheral venous cannula: A pilot study	16
Issue Highlights	16
Ethical concern regarding the UK PANORAMIC COVID‐19 trial	15
A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU	15
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	15
Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection	15
Challenging times: Delivering gene therapies and an opportunity for shared learning	15
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model	15
Issue Information	15
Association of state‐level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia	15
Cabotegravir PopPK analysis of adults and adolescents living with HIV/at risk for HIV receiving prep	15
Association of renin–angiotensin–aldosterone system inhibition with Covid‐19 hospitalization and all‐cause mortality in the UK biobank	15
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021	15
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis	15
A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg	15
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system	14
Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials	14
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis	14
Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats	14
Correction to “Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study”	14
Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis	14
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	14
Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus	14
	14
Issue Information	14
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	14
Sustainable medicines use in clinical practice: A clinical pharmacological view on eco‐pharmaco‐stewardship	14
Infliximab‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis	14
Appraising the visibility, relevance and impacts of clinical pharmacology	14
Issue Information	14
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2	13
Paediatric and obstetrical pharmacology – Pushing the frontier forward	13
Adherence levels and patterns for multiple cardiac medications prescribed to patients with incident atrial fibrillation events	13
Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist	13
Risk of out‐of‐hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs	13
A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects	13
Results of the first international quality control programme for oral targeted oncolytics	13
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis	13
Pharmacoethics and pregnancy: Overcoming the therapeutic orphan stigma	13
Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients	13

Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis	13
Identification and comparison of sex‐specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED)	13
Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales	13
Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis	13
Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism	13
Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials	12
Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4	12
Pro: Oximes should be used routinely in organophosphate poisoning	12
Assessment of the influence of body fat indices on antihypertensive drug responses	12
Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study	12
Beta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation	12
Trends in opioid prescribing in Scandinavian countries from 2010 to 2023: Insights from multi‐metric evaluation	12
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples	12
Issue Information	12
Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients	12
Risk of out‐of‐hospital cardiac arrest in antidepressant drug users	12
Nonchemotherapy drug‐induced cytopenias: A cost‐of‐illness study using the microcosting methodology based on real‐world data	12
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus	12
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study	12
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam	12
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease	12
Issue Information	12
Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing	12
Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?	12
Prescriptions of anti‐reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014–2022)	12
	12
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers	12
Issue Information	12
Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour	12
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV	12
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6	11
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B	11
Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories	11
Issue Information	11
Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia	11
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients	11
Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people	11
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma	11
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case report	11
Safe and supportive prescribing in transgender and non‐binary patients with cancer	11
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration	11
External validation of a therapeutic window for risperidone in children with autism spectrum disorder	11
Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis	11
Spotlight commentary: New Frontiers in pneumonia treatment	11
Clinical pharmacology in adolescent transgender medicine	11
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation	10
Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial	10
Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease	10
Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium	10
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients	10
Addition of direct oral anticoagulants to the World Health Organization model list of essential medicines for the treatment of atrial fibrillation: An African perspective	10
Clinical validation of clinical decision support systems for medication review: A scoping review	10
Off‐label and unlicensed medicine prescribing in university hospital paediatric wards in Finland: A prospective study	10
Concentrations of psychoactive substances in blood samples from non‐fatal and fatal opioid overdoses	10
Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib	10
Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus	10
Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation	10
Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings	10
Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne	10
Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers	10
Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam	10
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease	10
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	10
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials	10
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions	10
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin	10
Drug shortages. Part 1. Definitions and harms	10
The impact of curricular revision on student performance in pharmacology assessments	10
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants	10
Local variation in low carbon footprint inhalers in pre‐COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact	10
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols	10
Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study	10
Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19	10
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study	10
Implementability of opioid deprescribing interventions at transitions of care: A scoping review	10
Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4‐methylaminoantipyrine	10
Correction to “Minimizing prescribing errors: A phenomenological exploration of the views and experiences of independent prescribing pharmacists”	9
Population pharmacokinetic analysis of doravirine in real‐world people with HIV	9
Antiviral activity, safety and PK/PD of ACC017 in antiretroviral naïve HIV‐infected adults: A randomized, double‐blind, placebo/dose‐parallel‐controlled short‐term monotherapy study	9
Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens	9
Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis	9
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen	9
	9
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen	9
Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations	9
Skeletal muscle relaxant drug–drug–drug interactions and unintentional traumatic injury: Screening to detect three‐way drug interaction signals	9
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database	9
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects	9
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels	9
Pharmacokinetics of long‐acting cabotegravir and rilpivirine in seminal plasma throughout the dosing interval	9
Economic evaluations of therapeutic drug monitoring interventions in acute hospital‐based settings: A systematic review	9
Anthony Peck (1933–2021)	9
Twice neglected? Neglected diseases in neglected populations	9
Oxcarbazepine was associated with risks of newly developed hypothyroxinaemia and impaired central set point of thyroid homeostasis in schizophrenia patients	9
Call to action: Harmonization of pharmacovigilance regulations for post‐marketing pregnancy and breastfeeding safety studies	9